Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Mechanism-of-action and some adverse reaction claims align with the provided label excerpts, and cardiovascular risk-reduction is supported. However, multiple claims are not supported by the supplied label sections, including hunger/fullness effects, insulin sensitivity/glucose uptake, obesity/weight-loss indications, maintenance timing, monitoring requirements, long-term safety studied-not extensive, and specific drug-interaction examples (e.g., blood thinners, antibiotics). Several statements are overly broad versus what the label excerpts explicitly support. Safety-critical label areas (e.g., contraindications, boxed warnings, dosing/administration, full use-in-specific-populations) were not provided, limiting assessment.
Category Scores
Accurate Statements
Ozempic is also known as semaglutide.
Supported by 11 DESCRIPTION (OZEMPIC (semaglutide)).
Ozempic is a GLP-1 receptor agonist.
Supported by 12.1 Mechanism of Action (GLP-1 analogue; GLP-1 receptor agonist).
Ozempic works by mimicking a natural hormone that helps regulate blood sugar levels.
Supported by 12.1 (GLP-1 is a physiological hormone with actions on glucose; semaglutide acts as GLP-1 receptor agonist).
Ozempic stimulates the release of insulin.
Supported by 12.1 (stimulates insulin secretion, glucose-dependent).
Ozempic suppresses the release of glucagon.
Supported by 12.1 (lowers glucagon secretion, glucose-dependent).
Ozempic lowers blood sugar levels.
Supported by 12.1 (reduces blood glucose) and 1 INDICATIONS AND USAGE (improve glycemic control).
Ozempic improves glycemic control.
Supported by 1 INDICATIONS AND USAGE and 14.1 (HbA1c reductions).
Ozempic slows down gastric emptying.
Supported by 12.1 (minor delay in gastric emptying).
Nausea and vomiting can occur with Ozempic.
Supported by 6.1 (nausea, vomiting listed) and 5 (gastrointestinal adverse reactions).
Nausea and vomiting from Ozempic may occur particularly when first starting treatment.
Supported by 6.1: majority of reports of nausea/vomiting/diarrhea occurred during dose escalation.
Diarrhea can occur with Ozempic.
Supported by 6.1 (diarrhea listed).
Abdominal pain or discomfort can occur with Ozempic.
Supported by 6.1 (abdominal pain listed) and 5 gastrointestinal adverse reactions.
Ozempic has been shown to reduce the risk of major adverse cardiovascular events.
Supported by 1 INDICATIONS AND USAGE (reduce risk of major adverse cardiovascular events) and 14.2 (reduced MACE).
Ozempic can help reduce the risk of major adverse cardiovascular events such as heart attacks and strokes.
Supported by 1 INDICATIONS AND USAGE (MACE components include non-fatal myocardial infarction and non-fatal stroke) and 14.2.
Ozempic may interact with other medications, including diabetes medications.
Partially supported by 7.1 (interaction with insulin secretagogues such as sulfonylureas or insulin with increased hypoglycemia risk), but the claim is overly broad as written.
Unsupported Statements
In a study in the New England Journal of Medicine, participants receiving Ozempic lost an average of 10.3 pounds (4.7 kg) more than those receiving placebo over 26 weeks.
Not supported by the supplied label excerpts (no NEJM citation or 26-week 4.7 kg placebo comparison in provided sections).
Ozempic reduces hunger and increases feelings of fullness.
No supplied label excerpt describes hunger/fullness effects.
Ozempic stimulates the release of hormones that signal fullness.
No supplied label excerpt includes hormones signaling fullness.
Ozempic helps individuals feel more satisfied after eating.
No supplied label excerpt includes satiety/satisfaction after eating.
Ozempic improves insulin sensitivity.
No supplied label excerpt states improved insulin sensitivity.
Ozempic improves glucose uptake.
No supplied label excerpt states improved glucose uptake.
Ozempic helps the body use glucose for energy more efficiently.
No supplied label excerpt supports this phrasing.
Ozempic reduces the need for stored fat.
No supplied label excerpt addresses fat storage/use.
Ozempic may improve overall quality of life by reducing symptoms of type 2 diabetes and improving weight loss.
No supplied label excerpt supports quality-of-life or symptom improvement claims.
Diarrhea from Ozempic may be severe in some cases.
The provided excerpts do not state diarrhea specifically is severe; they discuss severe gastrointestinal adverse reactions generally.
Ozempic is approved for use in individuals with type 2 diabetes who have not achieved adequate glycemic control with other medications.
The supplied indication excerpt (1 INDICATIONS AND USAGE) does not specify this eligibility condition.
Ozempic has been shown to be effective in aiding weight loss in individuals who are obese.
No supplied label excerpt provides an indication or efficacy claim for weight loss in obese individuals.
Ozempic may be associated with significant weight loss in the first few weeks of treatment.
Provided excerpts only show weight changes at later timepoints (e.g., week 30/40/56), not 'first few weeks.'
After initial weight loss, continued treatment for several months may be needed to maintain weight loss.
No supplied label excerpt addresses weight-loss maintenance timing.
Regular monitoring and follow-up appointments with a healthcare provider are necessary to ensure Ozempic is working effectively and to address potential side effects.
No supplied label excerpt includes monitoring/follow-up requirements.
Ozempic has shown promise as a treatment for weight loss, particularly in individuals with type 2 diabetes.
No supplied label excerpt describes weight-loss 'promise' or weight loss as an indication.
The long-term safety of Ozempic has not been extensively studied.
No supplied label excerpt contains this statement.
Ozempic use in individuals without type 2 diabetes has not been extensively studied.
No supplied label excerpt contains this statement.
Ozempic use in conjunction with other weight loss medications has not been extensively studied.
No supplied label excerpt contains this statement.
Ozempic may interact with other medications, including blood thinners.
No supplied label excerpt mentions blood thinners.
Ozempic may interact with other medications, including certain antibiotics.
No supplied label excerpt mentions antibiotics.
Contradictions
Important Omissions
Dosing and administration details (e.g., initiation, titration, dose adjustments) were not evaluable because dosing/administration label sections were not provided.
Importance:
High
Contraindications, boxed warnings, and full warnings/precautions content were not evaluable because those label sections were not provided in full.
Importance:
High
Specific-population safety (e.g., pregnancy, pediatrics, renal/hepatic impairment) was not evaluable because those label sections were not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported and overly broad claims (e.g., specific interaction examples like blood thinners/antibiotics, severe diarrhea, weight-loss indications/maintenance, and monitoring requirements) could mislead clinical decision-making. Additionally, major safety-critical label areas (contraindications/boxed warning/dosing) were not included in the supplied excerpts, limiting assurance of on-label safety communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the provided label excerpts, including hunger/fullness mechanism, weight-loss/obesity and maintenance timing, certain interaction examples (blood thinners/antibiotics), severe diarrhea specificity, monitoring requirements, and study citation details (NEJM/26-week 4.7 kg). Also, some claims are overly broad versus explicitly stated indications (e.g., broad 'complications' risk reduction).
Suggested Improvement
Restrict claims to what is explicitly supported in the supplied label excerpts: for interactions, limit to insulin secretagogue/insulin and the stated gastric-emptying/oral medication caution; for adverse reactions, use label-supported terms and avoid unsupported severity assertions; for indications, avoid weight-loss/obesity claims and eligibility conditions not stated in the provided indication excerpt; remove unsupported study citation details not present in the label excerpts.